<DOC>
	<DOCNO>NCT00980109</DOCNO>
	<brief_summary>This multicenter , randomise , four arm placebo control study evaluate safety tolerability 10 mg inhale zanamivir day 75 mg oseltamivir capsule orally day relative placebo 16 week ( 112 day ) . Enrolled subject randomly assign 2:1:2:1 ratio ( active oseltamivir : placebo : active zanamivir : placebo ) one four study treatment group . It hypothesize oseltamivir zanamivir protect participant become infected influenza .</brief_summary>
	<brief_title>Long Term Influenza Prophylaxis With Inhaled Zanamivir Oral Oseltamivir</brief_title>
	<detailed_description>We plan recruit 130 non-pregnant subject include Health Care Workers , refer anyone work hospital , active arm 65 healthy , non-pregnant subject include Health Care Workers placebo arm total 390 study subject 4 study site Bangkok Nonthaburi province , Thailand : ( ) Faculty Medicine Siriraj Hospital , ( ii ) Bamrasnaradura Infectious Diseases Institute , ( iii ) Chest Disease Institute , ( iv ) Hospital Tropical Diseases . Randomisation Groups : Zanamivir inhalation , ( 5 mg per inhalation ) , two inhalation , daily use ROTADISK/DISKHALER 112 day . The dose administer approximately time day . Placebo ( lactose powder ) , two inhalation , daily use ROTADISK/ DISKHALER 112 day . The dose administer approximately time day . Oseltamivir capsule ( 75 mg per capsule ) , one capsule daily mouth ( PO ) 112 day . The dose administer approximately time day . Placebo capsule , one capsule daily 112 day . The capsule administer approximately time day . Study duration The study expect last 12 month . The study consist : - screen visit - 10 study visit : Days 0 , 7 ( +2 ) , 14 ( +2 ) , 28 ( +2 ) , 42 ( +2 ) , 56 ( +2 ) , 70 ( +2 ) , 84 ( +2 ) , 98 ( +2 ) 112 ( +2 ) - One follow-up visit Day 120 ( +2 )</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Healthy male female age 20 65 year . Healthy determine Investigator base medical history screen examination . 2 . Read understand study relate material intend subject . 3 . Signed informed consent prior study participation . 4 . Willingness ability comply study protocol duration trial . 5 . Female subject reproductive potential agrees use acceptable method birth control ( e.g. , intrauterine device , abstinence hormonal contraceptive drug ) throughout study ( D120+2 ) . 6 . For male subject , must agree use acceptable method birth control ( e.g . abstinence condom ) throughout study ( D120+2 ) . A subject eligible inclusion study follow apply : 1 . Females pregnant , try get pregnant lactating . 2 . Current history asthma chronic obstructive pulmonary disease within last 5 year . 3 . Abnormal pulmonary function test accord The Thoracic Society Thailand Guidelines Pulmonary Function Tests : ( ) FVC &lt; 80 % predict value age sex ( ii ) FEV1/FVC &lt; 70 % . ( see Appendix 2 ) 4 . Any chronic acute disease require treatment . 5 . An abnormal ECG indicate disease require immediate investigation treatment 6 . An abnormal chest xray indicate active disease process . 7 . A creatinine clearance &lt; 30 mL/min determine CockcroftGault equation ( see ) 8 . AST ALT â‰¥ 1.5 x ULN 9 . Use live attenuate influenza vaccine antiinfluenza drug within 14 day prior first dose study drugs/placebos . 10 . History alcohol substance abuse dependence opinion investigator would interfere subject compliance safety 11 . Subjects history allergy study drug drug class , history severe drug ( e.g . toxic epidermal necrolysis ) allergy ( e.g . previous history anaphylaxis ) , opinion investigator , contraindicate participation trial . 12 . The subject participate clinical trial receive investigational drug within 60 day prior first dose study drug . 13 . Subjects , opinion investigator , unlikely comply fully study procedure . 14 . History mental illness require hospitalisation outpatient psychiatric treatment within last 12 month 15 . Any suicidal attempt within previous 5 year . 16 . Screening HADS anxiety depression score &gt; 8 . 17 . Hemoglobin &lt; 11g/dL neutropenia &lt; 1000 per microlitre platelet count le 100,000 cells/mm3 Cockroft formula : CrCl ( mL/min ) = ( 140 age ) x Wt / 72 x serum creatinine ( female x 0.85 ) , age year , Wt kg , serum creatinine mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Influenza Prophylaxis</keyword>
	<keyword>Long Term</keyword>
	<keyword>Oral Oseltamivir</keyword>
	<keyword>Inhaled Zanamivir</keyword>
</DOC>